Annual Reports

 
Quarterly Reports

  • 10-Q (Aug 15, 2011)
  • 10-Q (May 16, 2011)
  • 10-Q (Nov 9, 2010)
  • 10-Q (Aug 9, 2010)
  • 10-Q (May 10, 2010)
  • 10-Q (Dec 10, 2009)

 
8-K

 
Other

MEDQUIST INC 10-Q 2011

Documents found in this filing:

  1. 10-Q
  2. Ex-31.1
  3. Ex-31.2
  4. Ex-32.1
  5. Ex-32.2
  6. Ex-32.2
MEDQ 3.31.11 10Q
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 10-Q
(Mark One)
þ
 
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the quarterly period ended March 31, 2011.
OR
o
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the transition period from  _____________ to _____________                    
Commission file number:0-19941
MEDQUIST INC.
(Exact name of Registrant as Specified in its Charter)
New Jersey
 
22-2531298
(State or Other Jurisdiction of
 
(I.R.S. Employer
Incorporation or Organization)
 
Identification No.)
 
 
 
9009 Carothers Parkway
 
 
 
 
 
Franklin, Tennessee
 
37067
(Address of Principal Executive Offices)
 
(Zip Code)
(856) 295-4600
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ     No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes o     No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o
Accelerated filerþ
Non-accelerated filer o
(Do not check if a smaller reporting company)
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o     No þ
The number of registrant’s shares of common stock, no par value, outstanding as of May 9, 2011 was 37,555,893.

MEDQUIST INC.
INDEX


PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
MedQuist Inc. and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share amounts)
Unaudited
 
Successor Company
 
Predecessor Company
 
For the period
February 12, to
March 31, 2011
 
For the period
January 1, to
February 11, 2011
 
For the three months ended
March 31, 2010
Net revenues
$
55,026
 
 
47,048
 
 
$
73,981
 
 
 
 
 
 
 
Operating costs and expenses:
 
 
 
 
 
Cost of revenues
35,192
 
 
29,987
 
 
49,833
 
Selling, general and administrative
5,846
 
 
5,219
 
 
8,797
 
Research and development
1,230
 
 
1,302
 
 
2,281
 
Depreciation
1,298
 
 
1,043
 
 
1,910
 
Amortization of intangible assets
2,800
 
 
1,511
 
 
1,820
 
Cost of legal proceedings, settlements and accommodations
(7,687
)
 
174
 
 
1,043
 
Acquisition and restructuring
3,212
 
 
278
 
 
954
 
 
 
 
 
 
 
Total operating costs and expenses
41,891
 
 
39,514
 
 
66,638
 
 
 
 
 
 
 
Operating income
13,135
 
 
7,534
 
 
7,343
 
 
 
 
 
 
 
Equity in income of affiliated company
 
 
 
 
514
 
Interest expense, net
(3,733
)
 
(3,115
)
 
(146
)
 
 
 
 
 
 
Income before income taxes
9,402
 
 
4,419
 
 
7,711
 
 
 
 
 
 
 
Income tax provision
762
 
 
453
 
 
367
 
 
 
 
 
 
 
Net income
$
8,640
 
 
3,966
 
 
$
7,344
 
 
 
 
 
 
 
Net income per share:
 
 
 
 
 
 
Basic
$
0.23
 
 
$
0.11
 
 
$
0.20
 
Diluted
$
0.23
 
 
$
0.10
 
 
$
0.20
 
 
 
 
 
 
 
Weighted average shares outstanding:
 
 
 
 
 
Basic
37,556
 
 
37,556
 
 
37,556
 
Diluted
37,786
 
 
37,852
 
 
37,556
 
The accompanying notes are an integral part of these consolidated financial statements.

1


MedQuist Inc. and Subsidiaries
Consolidated Balance Sheets
(In thousands)
Unaudited
 
Successor Company
 
Predecessor Company
 
March 31, 2011
 
December 31, 2010
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
31,829
 
 
$
41,265
 
Accounts receivable, net of allowance of $1,662 and $3,142, respectively
73,006
 
 
76,155
 
Other current assets
11,029
 
 
9,780
 
Total current assets
115,864
 
 
127,200
 
 
 
 
 
Property and equipment, net
15,256
 
 
14,135
 
Goodwill
89,292
 
 
88,982
 
Other intangible assets, net
103,248
 
 
79,860
 
Deferred income taxes
3,094
 
 
3,000
 
Other assets
10,050
 
 
10,741
 
Total assets
$
336,804
 
 
$
323,918
 
 
 
 
 
Liabilities and Shareholders’ Equity
 
 
 
Current liabilities:
 
 
 
Current portion of long term debt
$
 
 
$
20,000
 
Accounts payable
9,099
 
 
6,785
 
Accrued expenses
23,770
 
 
27,106
 
Accrued compensation
14,582
 
 
11,136
 
Current portion of lease obligations
284
 
 
758
 
Related party payable
2,043
 
 
5,386
 
Deferred revenue
9,392
 
 
10,840
 
Total current liabilities
59,170
 
 
82,011
 
Long term debt
260,000
 
 
265,000
 
Deferred income taxes
4,688
 
 
6,066
 
Other non-current liabilities
1,509
 
 
1,442
 
 
 
 
 
Commitments and contingencies
 
 
 
 
 
 
 
Shareholders’ equity:
 
 
 
Common stock — no par value; authorized 60,000 shares;
37,556 and 37,556 shares issued and outstanding, respectively
2,917
 
 
238,042
 
Retained earnings and accumulated deficit
8,640
 
 
(271,316
)
Accumulated other comprehensive (loss) income
(120
)
 
2,673
 
 
 
 
 
Total shareholders’ equity (deficit)
11,437
 
 
(30,601
)
 
 
 
 
Total liabilities and shareholders’ equity
$
336,804
 
 
$
323,918
 
The accompanying notes are an integral part of these consolidated financial statements.

2


MedQuist Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(In thousands)
Unaudited
 
Successor Company
 
Predecessor Company
 
For the period
February 12, to
March 31, 2011
 
For the period
January 1, to
February 11, 2011
 
For the three months ended
March 31, 2010
 
 
 
 
 
 
Net cash provided by operating activities
$
14,934
 
 
$
6,587
 
 
$
6,827
 
 
 
 
 
 
 
Investing activities:
 
 
 
 
 
Purchase of property and equipment
(1,654
)
 
(1,466
)
 
(1,737
)
Capitalized software
(1,243
)
 
(1,102
)
 
(925
)
Deposit for Spheris acquisition
 
 
 
 
(7,500
)
Net cash used in investing activities
(2,897
)
 
(2,568
)
 
(10,162
)
 
 
 
 
 
 
Financing activities:
 
 
 
 
 
Repayment of debt
 
 
(25,000
)
 
 
Payments on lease obligations
(252
)
 
(224
)
 
 
Debt issuance costs
 
 
 
 
(195
)
Net cash used in financing activities
(252
)
 
(25,224
)
 
(195
)
 
 
 
 
 
 
Effect of exchange rate changes
(9
)
 
(7
)
 
40
 
 
 
 
 
 
 
Net change in cash and cash equivalents
11,776
 
 
(21,212
)
 
(3,490
)
 
 
 
 
 
 
Cash and cash equivalents — beginning of period
20,053
 
 
41,265
 
 
25,216
 
 
 
 
 
 
 
Cash and cash equivalents — end of period
$
31,829
 
 
$
20,053
 
 
$
21,726
 
 
 
 
 
 
 
 
 
 
 
 
 
The accompanying notes are an integral part of these consolidated financial statements.
 

3


MedQuist Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(In thousands, except for per share amounts)
Unaudited
1. Basis of Presentation
The consolidated financial statements and footnotes thereto are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP) have been omitted pursuant to such rules and regulations although we believe that the disclosures are adequate to make the information presented not misleading. The consolidated financial statements include the accounts of MedQuist Inc. and all of its wholly-owned subsidiaries (the "Company"). All significant inter-company accounts and transactions have been eliminated in consolidation.
These statements reflect all normal recurring adjustments that, in the opinion of management, are necessary for the fair presentation of our results of operations, financial position and cash flows. Interim results are not necessarily indicative of results for a full year. The information in this Form 10-Q should be read in conjunction with the Company's 2010 Annual Report on Form 10-K for the year ended December 31, 2010 (the 2010 Form 10-K) filed with the Securities and Exchange Commission (SEC) on March 16, 2011.
On February 11, 2011 certain of the Company's shareholders entered into an exchange agreement with MedQuist Holdings Inc. ("MedQuist Holdings") which increased MedQuist Holdings' ownership interest in the Company to 82.2%. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 805-50-S99-1 “Business Combinations-Related issues” governs the application of push down accounting in situations where ownership is increased to 80% or more. The post-February 11, 2011 consolidated financial statements reflect the new basis of accounting as required by the authoritative guidance under ASC 805-50-S99-1, and have applied the SEC rules and guidance regarding “push down” accounting treatment. Accordingly, the Company's consolidated financial statements prior to the closing of the exchange agreement reflect the historical accounting basis in our assets and liabilities and are labeled Predecessor Company, while such consolidated financial statements subsequent to the exchange agreement are labeled Successor Company and reflect the push down basis of accounting for the fair values of assets and liabilities acquired by MedQuist Holdings in August 2008, rolled forward to February 11, 2011. This effect is presented in the Company's consolidated financial statements by a vertical black line division between the columns entitled Predecessor Company and Successor Company on the statements and relevant notes. The black line signifies that the amounts shown for the periods prior to and subsequent to the exchange agreement are not comparable. See Note 4, Change in Ownership.
MedQuist Holdings announced, effective March 11, 2011, that it had completed its public exchange offer under which it acquired additional shares of MedQuist Inc. common stock resulting in MedQuist Holdings now holding approximately 97% of the issued and outstanding shares of MedQuist Inc. In accordance with the terms of a Stipulation of Settlement entered into in connection with the settlement of MedQuist Inc. shareholder litigation and subject to final approval of the settlement by the Court, the remaining issued and outstanding shares of MedQuist Inc. are expected to be exchanged on the same terms as the public exchange in a short-form merger by the end of the third quarter of 2011. In connection with this expected short-form merger and to immediately reduce duplicate costs of being a public company, MedQuist Inc. gave formal written notice to NASDAQ to delist its shares traded under the ticker symbol, MEDQ. Shares of MedQuist Inc. common stock have ceased trading on NASDAQ and are currently trading on the Pink Sheets (as reported by the Pink Sheets LLC) under the symbol "MEDQ.PK".
2. Acquisition of Spheris Assets in the United States
On April 22, 2010, we and our shareholder, CBay Inc., completed the acquisition of substantially all of the assets of Spheris and certain of its affiliates, pursuant to the terms of the Stock and Asset Purchase Agreement. This acquisition provided substantial incremental volume growth and also provided opportunities for operating efficiencies and operating margin expansion. Costs incurred for the acquisition and direct integration costs are included in acquisition and restructuring on the accompanying statements of operations. The acquisition was funded from the proceeds of credit facilities entered into in connection with the acquisition.

4

MedQuist Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(In thousands, except for per share amounts)
Unaudited
 

The following unaudited pro forma summary presents the consolidated information of the Company as if the business combination had occurred at the beginning of the first quarter of 2010.
 
Pro Forma Three Months Ended
March 31, 2010
 
 
Net revenues
$
109,159
 
Net income
$
5,569
 
Net income per share (Basic)
$
0.15
 
Net income per share (Diluted)
$
0.15
 
 
These amounts have been calculated after applying our accounting policies and adjusting the results of Spheris to reflect the additional amortization of intangibles that would have been charged assuming the fair value adjustments to intangible assets had been applied from the beginning of the annual period being reported on, and the additional interest expense assuming the acquisition related debt had been incurred at the beginning of the period being reported on, excluding the acquisition costs, and including the related tax effects. Impacts of integration-related charges have been excluded from the amounts above, and per share amounts do not reflect the impacts of ownership changes that occurred during the first quarter of 2011. Additionally, the pro forma revenue amounts reflect only recognized revenues of the acquired business, but do not reflect the impacts of known losses that impacted the book of business in subsequent periods.
3. Debt
 
Debt consisted of the following:
 
Successor
 
Predecessor
 
March 31, 2011
 
December 31, 2010
Senior Secured Credit Facility consisting of:
 
 
 
Term loan
$
175,000
 
 
$
200,000
 
Revolving credit facility
 
 
 
Senior Subordinated Notes
85,000
 
 
85,000
 
 
260,000
 
 
285,000
 
Less: Current maturities
 
 
(20,000
)
Total long term debt
$
260,000
 
 
$
265,000
 
In January 2011 we made an optional prepayment of $20.0 million in addition to the $5.0 million due under the Senior Secured Credit Facility. No additional principal payments are required in 2011. In January 2011, as required under our Credit Agreement, we entered into interest rate cap contracts (for $60.0 million notional amounts which will amortize over time) to provide coverage for fluctuation in interest rates. The interest rates on the term loan and the Senior Subordinated Notes were 7.25% and 13.0% respectively on March 31, 2011.
As of March 31, 2011, we believe we were in compliance with the covenants of our debt.
 
4. Change in Ownership
On February 11, 2011, MedQuist Holdings acquired additional shares of our common stock in a private exchange with certain of our shareholders, which resulted in their ownership increasing to over 80%. Effective February 11, 2011, we adopted the provisions of push down accounting. Accordingly the purchase accounting adjustments recorded at MedQuist Holdings related to the purchase of a 69.5% interest in us on August 6, 2008, as rolled forward to February 11, 2011, were recorded on our books and records. The basis pushed down to us is the basis recorded by MedQuist Holdings as of August 6, 2008, the transaction date, adjusted for activities recorded by MedQuist Holdings through February 11, 2011.

5


The following amounts were recorded on our financial records on February 11, 2011.
 
Recorded as of
February 11, 2011
 Current assets
$
924
 
 Property & equipment
88
 
Goodwill
339
 
 Intangible assets other than goodwill
25,655
 
Deferred taxes
2,567
 
Total assets
$
29,573
 
Increase in Shareholders' Equity
$
29,573
 
The impact on our Shareholders' equity was adjusted to reflect the new basis of accounting effective at the time that ownership increased to more than 80%. Accordingly, the equity accounts on Predecessor Company were not carried over to Successor Company. Successor Company beginning equity as of February 11, 2011 represents the net assets of Successor Company as valued with the impact of push down accounting.
5. Comprehensive Income
Comprehensive income was as follows:
 
Successor Company
 
Predecessor Company
 
For the Period
February 12 - March 31
 
For the Period
January 1 - February 11
 
Three months ended March 31,
 
2011
 
2011
 
2010
Net income
$
8,640
 
 
$
3,966
 
 
$
7,344
 
Foreign currency translation adjustment
(120
)
 
(105
)
 
(299
)
Comprehensive income
$
8,520
 
 
3,861
 
 
$
7,045
 
6. Net Income per Share
Basic net income per share is computed by dividing net income by the weighted average number of shares outstanding during each period. Diluted net income per share is computed by dividing net income by the weighted average shares outstanding, as adjusted for the dilutive effect of common stock equivalents, which consist only of stock options, using the treasury stock method.
The following table reflects the weighted average shares outstanding used to compute basic and diluted net income per share:
 
Successor Company
 
Predecessor Company
 
For the Period
February 12 - March 31
 
For the Period
January 1 - February 11
 
Three months ended March 31,
 
2011
 
2011
 
2010
Net income
$
8,640
 
 
$
3,966
 
 
$
7,344
 
Weighted average shares outstanding:
 
 
 
 
 
Basic
37,556
 
 
37,556
 
 
37,556
 
Effect of dilutive shares
230
 
 
296
 
 
 
Diluted
37,786
 
 
37,852
 
 
37,556
 
Net income per share:
 
 
 
 
 
Basic
$
0.23
 
 
$
0.11
 
 
$
0.20
 
Diluted
$
0.23
 
 
$
0.10
 
 
$
0.20
 
 

6

MedQuist Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(In thousands, except for per share amounts)
Unaudited
 

7. Accrued Expenses
Accrued expenses consisted of the following:
 
Successor Company
 
Predecessor Company
 
March 31, 2011
 
December 31, 2010
Customer accommodations
$
729
 
 
$
10,387
 
Accrued interest
5,442
 
 
5,593
 
Restructure
4,424
 
 
2,214
 
Transaction fees incurred
3,426
 
 
 
Other (no item exceeds 5% of current liabilities)
9,749
 
 
8,912
 
Total accrued expenses
$
23,770
 
 
$
27,106
 
2011 Restructuring Plan
On March 31, 2011, our board of directors adopted a restructuring plan (2011Restructuring Plan) to complete the integration of the acquired Spheris operations into MedQuist Inc. This integration resulted in termination costs of approximately $1.1 million in the first quarter of 2011 from a related reduction in workforce and a charge of $1.5 million in the first quarter of 2011 representing future lease payments on the Company's former corporate headquarters in Mt. Laurel, New Jersey and lease termination costs for the former data center in Sterling, Virginia, offset by estimated sublease rentals. The future minimum lease payments on the Mt. Laurel facility total $2.5 million.
The Company expects that restructuring activities may continue in 2011 as management identifies additional opportunities for synergies resulting from the acquisition of Spheris including the elimination of redundant functions.
The table below reflects the financial statement activity related to the 2011 Restructuring Plan.
 
For the Period February 12, 2011
to March 31, 2011
 
For the Period January 1, 2011
to February 11, 2011
Beginning balance
$
 
 
$
 
Charge
2,528
 
 
 
Cash paid
 
 
 
Ending balance
$
2,528
 
 
$
 
 
2010 Restructuring Plan
Management’s ongoing cost reduction initiatives, including process improvement, combined with the acquisition of Spheris, resulted in a restructuring plan (2010 Restructuring Plan) involving staff reductions and other actions designed to maximize operating efficiencies.
The table below reflects the financial statement activity related to the 2010 Restructuring Plan.
 
Successor Company
 
Predecessor Company
 
For the Period February 12, 2011 to
March 31, 2011
 
For the Period January 1, 2011 to
February 11, 2011
Year Ended
December 31, 2010
Beginning balance
$
1,889
 
 
$
2,039
 
$
 
Charge
 
 
 
3,460
 
Cash paid
(165
)
 
(150
)
(1,421
)
Ending balance
$
1,724
 
 
$
1,889
 
$
2,039
 
 
No other restructuring plan has a material impact on our balance sheets, results of operations or cash flows.

7


8. Cost of Legal Proceedings , Settlements and Accommodations
 
The following is a summary of the amounts recorded as cost of legal proceedings, settlements and accommodations in the accompanying consolidated statements of operations.
 
 
Successor Company
 
Predecessor Company
 
 
For the period February 12, 2011 to
March 31, 2011
 
For the period January 1, 2011 to
February 11, 2011
 
For the three months ended
March 31,2010
Professional fees and settlements
 
$
1,971
 
 
$
174
 
 
$
1,043
 
Accommodation reversal
 
(9,658
)
 
 
 
 
Totals
 
$
(7,687
)
 
$
174
 
 
$
1,043
 
On March 31, 2011, our board of directors terminated the Customer Accommodation Program. As a result, any amounts that had not been offered to customers were reversed, leaving a balance of approximately $0.7 million. Professional fees and settlements in the period February 12, 2011 to March 31, 2011 includes a settlement of indemnification claims with our former chief financial officer, which will reduce future legal fees we would otherwise be required to pay pursuant to the indemnification obligations contained in our bylaws.
In November 2003, one of our employees raised allegations that we had engaged in improper billing practices. In response, our board of directors undertook an independent review of these allegations (Review). In response to our customers’ concern over the public disclosure of certain findings from the Review, we made the decision in the fourth quarter of 2005 to take action to try to avoid litigation and preserve and solidify our customer business relationships by offering a financial accommodation to certain of our customers.
In connection with our decision to offer financial accommodations to certain of our customers (Accommodation Customers), we analyzed our historical billing information and the available report-level data to develop individualized accommodation offers to be made to Accommodation Customers (Accommodation Analysis). Based on the Accommodation Analysis, our board of directors authorized management to make cash or credit accommodation offers to Accommodation Customers in the aggregate amount of $75,818 (Customer Accommodation Program). By accepting our accommodation offer, the customer agreed, among other things, to release us from any and all claims and liability regarding the billing related issues. On March 31, 2011, our board of directors terminated the Customer Accommodation Program. As a result, any amounts that had not been offered to customers were reversed.
9. Income Taxes
Our consolidated income tax expense consists principally of an increase in deferred tax liabilities related to goodwill amortization deductions for income tax purposes during the applicable period as well as state and foreign income taxes. We recorded a valuation allowance to reduce our net deferred tax assets to an amount that is more likely than not to be realized in future years.
Effective with the completion of the exchange on February 11, 2011, we will file federal and certain states short period tax returns for the period January 1, 2011 to February 11, 2011. For periods after February 11, 2011, we will file our income tax returns as part of the MedQuist Holdings consolidated tax return filings. We do not expect these changes to materially impact our income tax expense, cash payments, refunds, or our ability to use net operating losses during 2011.
We expect that our consolidated income tax expense for the year ended December 31, 2011, similar to the year ended December 31, 2010, will consist principally of an increase in deferred tax liabilities related to goodwill amortization deductions for income tax purposes during the applicable year as well as state and foreign income taxes. We regularly assess the future realization of deferred taxes and whether the valuation allowance against the majority of domestic deferred tax assets is still warranted. To the extent sufficient positive evidence, including past results and future projections, exists to benefit all or part of these benefits, the valuation allowance will be released accordingly. It is reasonably possible that all or a portion of the valuation allowance will be released within the next year.

8


10. Commitments and Contingencies
Shareholder Settlement
On February 8, 2011 and February 10, 2011, two of MedQuist Inc.'s minority shareholders filed class action complaints in the Superior Court of New Jersey, Burlington County, Chancery Division, (the Court) against us, the individual members on MedQuist Inc.'s board of directors and MedQuist Holdings (the Shareholder Litigation). Plaintiffs alleged that the defendants breached certain fiduciary duties they owed to minority shareholders of MedQuist Inc. in connection with the structuring and disclosure of the Public Exchange Offer.
On March 4, 2011, the parties to the Shareholder Litigation entered into a memorandum of understanding (the MOU) that outlined the material terms of a proposed settlement of the Shareholder Litigation. Under the terms of the MOU, MedQuist Holdings agreed to extend the expiration of the Public Exchange Offer and further agreed that if, as a result of the Registered Exchange Offer, they obtained ownership of at least 90% of the outstanding our common stock they would conduct a short-form merger under applicable law to acquire the remaining shares of our common stock that they do not currently own at the same exchange ratio applicable under the Public Exchange Offer. We agreed to make certain supplemental disclosures concerning the Public Exchange Offer, which were contained in an amendment to Schedule 14D-9 that we filed with the SEC on March 7, 2011. We also agreed to use our best efforts to finalize a Stipulation of Settlement (the Settlement Stipulation) and present it to the Court for preliminary approval within thirty days of the date of the MOU.
On April 1, 2011, the parties finalized the Settlement Stipulation that contained all the terms of the parties' proposed settlement of the Shareholder Litigation. Among other things, the Settlement Stipulation recognized that, subject to court approval, a non-opt out settlement class would be certified consisting of all holders of our common stock, except the defendants and their immediate families and their affiliates (the Class). The Settlement Stipulation acknowledged that updated disclosures were made with respect to the Public Exchange Offer and that the Public Exchange Offer expiration date was extended until March 11, 2011. The Settlement Stipulation also memorialized the parties' agreement that, following Court approval, MedQuist Holdings would conduct a short-form merger to acquire the remaining shares of our common stock at the same exchange ratio applicable under the Public Exchange Offer.
On April 19, 2011, the Court held a hearing to review the Settlement Stipulation and determine whether to preliminarily approve the settlement. On this same date, the Court entered a preliminary approval order (the Preliminary Approval Order) that, among other things, certified the Class for settlement purposes, set deadlines for providing notice of the settlement to Class members, and scheduled June 17, 2011 as the return date for a fairness hearing to determine final approval of the settlement. The Preliminary Approval Order also set May 27, 2011, as the deadline for the filing of a motion for final approval of the settlement, and June 3, 2011, as the deadline for any Class members to file objections to the settlement. The settlement will not become final until the Court determines, following a hearing, that the terms of the settlement are fair, reasonable and adequate, and in the best interests of the Settlement Class.
SEC Investigation of Former Officer
With respect to our historical billing practices, the SEC pursued civil litigation against our former chief financial officer, whose employment ended in July 2004. Pursuant to our bylaws, we had been providing indemnification for the legal fees for our former chief financial officer. In February 2011 we reached a settlement under which our former chief financial officer released us from our indemnification obligations to him upon his settlement of the litigation with the SEC and our payment to him of a negotiated amount. The former chief financial officer settled the SEC litigation and we made our settlement payment to him in May 2011. This settles the last remaining contingency related to our billing practices.
11. Related Party Transactions
MedQuist Holdings (previously CBay Inc.) has an approximately 97% ownership interest in us at March 31, 2011.
We have an agreement with CBay Systems & Services, Inc., (CBay Systems), a wholly-owned subsidiary of our majority shareholder, under which we outsource medical transcription services to CBay Systems. We incurred expenses of $11,470 and $3,634 for the three months ended March 31, 2011 and 2010, respectively. All medical transcription expenses for both periods were recorded in cost of revenues in the accompanying consolidated statements of operations.
We also have a subcontracting agreement with CBay Systems, pursuant to which CBay Systems subcontracts medical transcription, editing and related services to us. For the three months ended March 31, 2011 and 2010, we recorded revenue of $671 and $531 respectively, under the terms of the subcontracting agreement.

9

MedQuist Inc. and Subsidiaries
Notes to Consolidated Financial Statements
(In thousands, except for per share amounts)
Unaudited
 

We have a Management Services Agreement with CBay Inc. pursuant to which certain senior executives and directors of CBay Inc. provide advisory and consulting services. The Management Services Agreement provides that, in consideration of the management services rendered by CBay Inc. to us since July 1, 2009 we pay CBay Inc. a quarterly services fee equal to $350, payable in arrears. For the three month periods ending March 31, 2011 and 2010, we incurred $350 in services expenses with CBay Inc. All Management Services Agreement costs incurred have been recorded as selling, general and administrative expenses in the accompanying consolidated statements of operations.
As of March 31, 2011 and December 31, 2010, the related party payable in the accompanying consolidated balance sheets reflected $5.8 million due to CBay Inc. and CBay Systems, net of $3.8 million due from MedQuist Holdings for transaction costs paid by us on behalf of MedQuist Holdings. Additionally, accounts receivable in the accompanying consolidated balance sheets as of March 31, 2011 and December 31, 2010 included $745 and $396, respectively, for amounts due from CBay Systems.
12. Assets and Liabilities Measured at Fair Value
Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity's own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).
Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity's own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.
Derivative financial instruments
The Company uses interest rate caps to manage its interest rate risk. As of March 31, 2011, the Company has interest rate cap contracts for $60.0 million in notional amounts, which will amortize over time, to provide coverage for fluctuation in interest rates. The valuation of these instruments is determined using widely accepted valuation techniques including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate caps are determined using the market standard methodology of discounting the future expected cash receipts that would occur if variable interest rates rise above the strike rate of the caps.  The variable interest rates used in the calculation of projected receipts on the cap are based on an expectation of future interest rates derived from observable market interest rate curves and volatilities.  To comply with the provisions of ASC 820, the Company incorporates credit valuation adjustments to appropriately reflect the respective counterparty's nonperformance risk in the fair value measurements.
Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by its counterparties. For counterparties with publicly available credit information, the credit spreads over LIBOR used in the calculations represent implied credit default swap spreads obtained from a third party credit data provider. However, as of March 31, 2011, the Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of the derivatives. As a result, the Company has determined that its valuations for the foreign currency exchange contracts in their entirety are classified in Level 2 of the fair value hierarchy.

10


The Company's assets and liabilities measured at fair value on a recurring basis as of March 31, 2011, are as follows.
 
Asset at
March 31, 2011
Interest rate agreements
$
61
 
 
The interest rate derivatives are classified in other assets, with related gains and losses recorded in interest expense, net.

11


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This report contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, the industry in which we operate and other matters, as well as management’s beliefs and assumptions and other statements regarding matters that are not historical facts. These statements include, in particular, statements about our plans, strategies and prospects. For example, when we use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 21E of the Securities Exchange Act of 1934 (Exchange Act). Our forward-looking statements are subject to risks and uncertainties. Actual events or results may differ materially from the results anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors that could cause actual results to differ materially from those estimated by us include the risk factors set forth in the in our Annual Report on Form 10-K for the year ended December 31, 2010 (2010 Form 10-K). These and other risks and uncertainties that could affect our actual results are discussed in this report and in our other filings with the SEC.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, events, levels of activity, performance, or achievements. We do not assume responsibility for the accuracy and completeness of the forward-looking statements other than as required by applicable law. We do not undertake any duty to update any of the forward-looking statements after the date of this report to conform them to actual results, except as required by the federal securities laws.
You should read this section in combination with the section entitled Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2010, included in the 2010 Form 10-K.
Executive Overview
We are a leading provider of integrated clinical documentation solutions for the U.S. healthcare system. Our end-to-end solutions convert physicians’ dictation of patient interactions, or the physician narrative, into a high quality and customized electronic record. These solutions integrate technologies and services for voice capture and transmission, automated speech recognition (ASR), medical transcription and editing, workflow automation, and document management and distribution to deliver a complete managed service for our customers. Our solutions enable hospitals, clinics, and physician practices to improve the quality of clinical data as well as accelerate and automate the documentation process, and we believe our solutions improve physician productivity and satisfaction, enhance revenue cycle performance, and facilitate the adoption and meaningful use of electronic health records.
Volume and Pricing Trends
The vast majority of our revenue is generated by providing clinical documentation services to our customers. Product sales and related maintenance contracts and other make up the balance of our net revenues. Our customers are generally charged a rate per character multiplied by the number of characters that we process.
We base our pricing on various factors, principally market forces, the extent to which we can utilize our offshore production facilities, the extent to which customers utilize the ASR technology available in our solutions, the scope of services provided, and turnaround times requested by a particular customer. We work with our customers to evaluate how different solutions affect pricing and to determine what for them is an optimal mix of service level and price. Higher utilization of offshore production and ASR leads to lower costs for us, which permits us to offer better pricing to our customers while at the same time contributing to margin growth. We have successfully migrated a significant portion of our volume offshore and we will continue these efforts.
As technological advances and increased use of offshore resources have driven down industry costs, the average price per character has also declined as healthcare providers have sought to participate in the economic gains. We intend to monitor and adjust our pricing accordingly to remain competitive as these industry trends continue.
Operating Improvements
Cost of revenues on a per unit basis has declined versus the prior year period due to the increased percentage of volume produced offshore and the increased utilization of ASR technology as well as reductions of support staff headcount as we shift volume to India in order to further reduce operating costs. Our use of ASR technology has increased to 72% for the quarter ended March 31, 2011, compared to 57% for the same period in 2010. As we continue to increase the use of ASR technology and move volume offshore, we expect to continue to reduce costs. Some of our contracts specify lower prices for work performed offshore or using speech recognition technology. Therefore, our operating income will not increase by the full amount of the savings we realize.

12


Critical Accounting Policies, Judgments and Estimates
There have been no material changes in our critical accounting policies, judgments or estimates as disclosed in our 2010 Form 10-K except as discussed below.
Customer Accommodation Program
In response to customers’ concerns regarding historical billing matters, we established a plan to offer financial accommodations to certain of our customers during 2005 and 2006 and recorded the related liability. Since 2008, we have not made additional offers. In March 2011, our board of directors terminated the Customer Accommodation Program.
Acquisition of Spheris Inc. Assets and Related Debt Incurred
We and our majority shareholder, CBay Inc., completed the acquisition of substantially all of the assets of Spheris. Spheris provided medical transcription services in the United States. This acquisition provided substantial incremental volume growth and also provided opportunities for operating efficiencies and operating margin expansion. Costs incurred for the Spheris acquisition and direct integration costs are included in the line item acquisition and restructuring in the accompanying consolidated statements of operations.
The following unaudited pro forma summary presents the consolidated information of the Company as if the business combination had occurred at the beginning of 2010.
 
Predecdessor Company
 
Pro Forma Three Months
Ended March 31, 2010
 
(in thousands, except per share amount)
Net revenues
$
109,159
 
Net income
$
5,569
 
Net income per share (Basic)
$
0.15
 
Net income per share (Diluted)
$
0.15
 
These amounts have been calculated after applying the Company’s accounting policies and adjusting the results of Spheris to reflect the additional amortization of intangibles that would have been charged assuming the fair value adjustments to intangible assets had been applied from the beginning of the annual period being reported on, and the additional interest expense assuming the acquisition related debt had been incurred at the beginning of the annual period being reported on, excluding the acquisition costs, and including the related tax effects.
Consolidated Results of Operations
For purposes of providing a comparison between our 2011 results and the corresponding 2010 periods, we have presented our 2011 results as the mathematical addition of the Predecessor Company and Successor Company each of which are GAAP financial measures, for the three months ended March 31, 2011. We believe that this presentation provides the most meaningful information about our results of operations. This approach is not consistent with GAAP, may yield results that are not strictly comparable on a period-to-period basis, and may not reflect the actual results we would have achieved.

13


We have presented a reconciliation of our financial statements to the combined total, which is a non-GAAP financial measure.
 
Successor Company
 
Predecessor Company
 
Combined Total
 
For the period
February 12, to
March 31, 2011
 
For the period
January 1, to
February 11, 2011
 
For the three months ended
March 31, 2011
Net revenues
$
55,026
 
 
$
47,048
 
 
$
102,074
 
Operating costs and expenses:
 
 
 
 
 
 
Cost of revenues
35,192
 
 
29,987
 
 
65,179
 
Selling, general and administrative
5,846
 
 
5,219
 
 
11,065
 
Research and development
1,230
 
 
1,302
 
 
2,532
 
Depreciation
1,298
 
 
1,043
 
 
2,341
 
Amortization of intangible assets
2,800
 
 
1,511
 
 
4,311
 
Cost of legal proceedings, settlements and accommodations
(7,687
)
 
174
 
 
(7,513
)
Acquisition and restructuring
3,212
 
 
278
 
 
3,490
 
Total operating costs and expenses
41,891
 
 
39,514
 
 
81,405
 
Operating income
13,135
 
 
7,534
 
 
20,669
 
Equity in income of affiliated company
 
 
 
 
 
Interest expense, net
(3,733
)
 
(3,115
)
 
(6,848
)
Income before income taxes
9,402
 
 
4,419
 
 
13,821
 
Income tax provision
762
 
 
453
 
 
1,215
 
Net income
$
8,640
 
 
$
3,966
 
 
$
12,606
 

14


 
The following tables set forth our consolidated results of operations for the three months ended March 31, 2011 and 2010.
 
MedQuist Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
Unaudited
 
Three Months Ended March 31,
 
 
 
 
 
2011
 
2010
 
 
 
Change in
 
 
 
% of Net
 
 
 
% of Net
 
 
 
% of Net
($ in thousands)
Amount
 
Revenues
 
Amount
 
Revenues
 
$ Change
 
Revenues
Net revenues
$
102,074
 
 
100.0
 %
 
$
73,981
 
 
100.0
 %
 
$
28,093
 
 
 
Operating costs and expenses:
 
 
 
 
 
 
 
 
 
 
 
Cost of revenues
65,179
 
 
63.9
 %
 
49,833
 
 
67.4
 %
 
15,346
 
 
(3.5
)%
Selling, general and administrative
11,065
 
 
10.8
 %
 
8,797
 
 
11.9
 %
 
2,268
 
 
(1.1
)%
Research and development
2,532
 
 
2.5
 %
 
2,281
 
 
3.1
 %
 
251
 
 
(0.6
)%
Depreciation
2,341
 
 
2.3
 %
 
1,910
 
 
2.6
 %
 
431
 
 
(0.3
)%
Amortization of intangible assets
4,311
 
 
4.2
 %
 
1,820
 
 
2.5
 %
 
2,491
 
 
1.8
 %
Cost of legal proceedings, settlements and accommodations
(7,513
)
 
(7.4
)%
 
1,043
 
 
1.4
 %
 
(8,556
)
 
(8.8
)%
Acquisition and restructuring
3,490
 
 
3.4
 %
 
954
 
 
1.3
 %
 
2,536
 
 
2.1
 %
Total operating costs and expenses
81,405
 
 
79.8
 %
 
66,638
 
 
90.1
 %
 
14,767
 
 
(10.3
)%
Operating income
20,669
 
 
20.2
 %
 
7,343
 
 
9.9
 %
 
13,326
 
 
10.3
 %
Equity in income of affiliated company
 
 
 
 
514
 
 
0.7
 %
 
(514
)
 
(0.7
)%
Interest expense, net
(6,848
)
 
(6.7
)%
 
(146
)
 
(0.2
)
 
(6,702
)
 
(6.5
)%
Income before income taxes
13,821
 
 
13.5
 %
 
7,711
 
 
10.4
 %
 
6,110
 
 
3.1
 %
Income tax provision
1,215
 
 
1.2
 %
 
367
 
 
0.5
 %
 
848
 
 
0.7
 %
Net income
$
12,606
 
 
12.3
 %
 
$
7,344
 
 
9.9
 %
 
$
5,262
 
 
2.4
 %
Net revenues
Net revenues increased $28.1 million, or 38%, to $102.1 million for the three months ended March 31, 2011 compared with $74.0 million for the three months ended March 31, 2010. The acquisition of Spheris contributed approximately $31.0 million in net revenues for the three months ended March 31, 2011 versus the same period in the prior year.
Cost of revenues
Cost of revenues were $65.2 million for the three months ended March 31, 2011 compared with $49.8 million for the three months ended March 31, 2010. As a percentage of net revenues, cost of revenues decreased to 63.9% for the three months ended March 31, 2011 from 67.4% for the same period in the prior year primarily due to increased utilization of speech recognition technologies, increased utilization of offshore resources, and other operating cost reduction initiatives. The increase in total dollars versus the prior year period was primarily due to direct incremental costs associated with the incremental Spheris volumes.
Selling, general and administrative
SG&A expenses were 10.8% of net revenues for the three month period ended March 31, 2011 compared to 11.9% for the same period in the prior year. The decrease versus prior year is due to the impact of synergies realized from the Spheris acquisition and other cost savings initiatives.

15


Research & development
R&D expenses as a percentage of net revenues were 2.5% for the three months ended March 31, 2011 compared to 3.1% for the same period in the prior year. This decrease was due to the impact of synergies realized from the Spheris acquisition.
Depreciation
Depreciation expense as a percentage of net revenues was 2.3% for the three months ended March 31, 2011 compared to 2.6% for the same period in the prior year.
Amortization
Amortization expense as a percentage of net revenues was 4.2% for the three months ended March 31, 2011 compared to 2.5% for the same period in the prior year. This increase was primarily due to amortization of acquired intangible assets associated with the acquisition of Spheris and the effect of the push down accounting commencing on February 12, 2011.
Cost of legal proceedings, settlements and accommodations
Costs of legal proceedings, settlements and accommodations as a percentage of net revenues were (7.4%) for the three month period ended March 31, 2011 compared to 1.4% for the same period in the prior year. During the three months ended March 31, 2011, our board of directors terminated the Customer Accommodation Program and we reversed $9.7 million of the accrual. We also recorded a charge for a settlement of our indemnification obligations with our former chief financial officer and fees in connection with the shareholder litigation.
Acquisition and restructuring
We incurred acquisition and restructuring charges of $3.5 million for the three months ended March 31, 2011. During the three months ended March 31, 2011, we recorded net restructuring charges of $2.6 million including approximately $1.0 million from a reduction in workforce and a charge of $1.5 million representing future lease payments on the Company's former corporate headquarters in Mt. Laurel, New Jersey and former data center in Sterling, Virginia, offset by expected sublease rentals. The future minimum lease payments on the Mt. Laurel facility total $2.5 million.
We expect that restructuring activities may continue in 2011 as management identifies opportunities for synergies resulting from the acquisition of Spheris including the elimination of redundant functions.
Interest expense, net
Interest expense during the three months ended March 31, 2011 was $6.8 million, which is related to our debt and the amortization of debt issuance costs.
Income tax provision
The effective income tax rate was 8.8% and 4.8% for the three month periods ended March 31, 2011 and 2010, respectively.
Our consolidated income tax expense consists principally of an increase in deferred tax liabilities related to goodwill amortization deductions for income tax purposes during the applicable period as well as state and foreign income taxes. We recorded a valuation allowance to reduce our net deferred tax assets to an amount that is more likely than not to be realized in future years.
Effective with the completion of the exchange on February 11, 2011, we will file federal and certain states short period tax returns for the period January 1, 2011 to February 11, 2011. For periods after February 11, 2011, we will file our income tax returns as part of the MedQuist Holdings Inc. consolidated tax return filings. We do not expect these changes to materially impact our income tax expense, cash payments, refunds, or our ability to use net operating losses during 2011.
We expect that our consolidated income tax expense for the year ended December 31, 2011, similar to the year ended December 31, 2010, will consist principally of an increase in deferred tax liabilities related to goodwill amortization deductions for income tax purposes during the applicable year as well as state and foreign income taxes. We regularly assess the future realization of deferred taxes and whether the valuation allowance against the majority of domestic deferred tax assets is still warranted. To the extent sufficient positive evidence, including past results and future projections, exists to benefit all or part of these benefits, the valuation allowance will be released accordingly. It is reasonably possible that all or a portion of the valuation allowance will be released within the next year.

16


Liquidity and Capital Resources
Our principal sources of liquidity include cash generated from operations, available cash on hand, and availability under our revolving credit facility. Cash provided by operating activities was $21.5 million for the three months ended March 31, 2011 versus $6.8 million provided by operations for the same period prior year. Some of the significant items impacting operating cash flows during the current year period included:
Improvements in operating income, which increased to $20.7 million for the three months ended March 31, 2011 compared to $7.3 million for the same period prior year.
In working capital for the quarter, we saw improved collections of accounts receivable balances which provided $2.6 million of cash in the current period. Accounts payable and accrued expenses were a $3.8 million use of cash, accrued compensation provided $3.5million, while deferred revenues were a use of cash of $1.2 million.
Capital spending in the quarter was $5.5 million for both purchases and internally developed software projects.
We made no acquisitions in the quarter ended March 31, 2011.
We believe our existing cash, cash equivalents, and cash to be generated from operations and available borrowings under our revolving credit facility will be sufficient to finance our operations for the next twelve months. However, if we fail to generate adequate cash flows from operations in the future, due to an unexpected decline in our net revenues, or due to increased cash expenditures in excess of the net revenues generated, then our cash balances may not be sufficient to fund our continuing operations without obtaining additional debt or selling additional equity. There are no assurances that sufficient funding from external sources will be available to us on acceptable terms, if at all.
Off-Balance Sheet Arrangements
We are not involved in any off-balance sheet arrangements that have or are reasonably likely to have a material current or future impact on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources. In January 2011, as required under our Credit Agreement, we entered into interest rate cap contracts (for $60.0 million notional amounts which will amortize over time) to provide coverage for fluctuation in interest rates.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management with the participation of our chief executive officer and our chief financial officer evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15, Securities Exchange Act of 1934 (the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, management is required to apply its judgment in evaluating the benefits of possible disclosure controls and procedures relative to their costs to implement and maintain.
Based on management’s evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There have been no changes in our internal control over financial reporting during the fiscal quarter ended March 31, 2011 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

17


PART II. OTHER INFORMATION
Item 1. Legal Proceedings
Shareholder Settlement
On February 8, 2011 and February 10, 2011, two of MedQuist Inc.'s minority shareholders filed class action complaints in the Superior Court of New Jersey, Burlington County, Chancery Division, (the Court) against us, the individual members on MedQuist Inc.'s board of directors and MedQuist Holdings Inc. (the Shareholder Litigation). Plaintiffs alleged that the defendants breached certain fiduciary duties they owed to minority shareholders of MedQuist Inc. in connection with the structuring and disclosure of the Public Exchange Offer.
On March 4, 2011, the parties to the Shareholder Litigation entered into a memorandum of understanding (the MOU) that outlined the material terms of a proposed settlement of the Shareholder Litigation. Under the terms of the MOU, MedQuist Holdings Inc. agreed to extend the expiration of the Public Exchange Offer and further agreed that if, as a result of the Registered Exchange Offer, they obtained ownership of at least 90% of the outstanding our common stock they would conduct a short-form merger under applicable law to acquire the remaining shares of our common stock that they do not currently own at the same exchange ratio applicable under the Public Exchange Offer. We agreed to make certain supplemental disclosures concerning the Public Exchange Offer, which were contained in an amendment to Schedule 14D-9 that we filed with the SEC on March 7, 2011. We also agreed to use our best efforts to finalize a Stipulation of Settlement (the Settlement Stipulation) and present it to the Court for preliminary approval within thirty days of the date of the MOU.
On April 1, 2011, the parties finalized the Settlement Stipulation that contained all the terms of the parties' proposed settlement of the Shareholder Litigation. Among other things, the Settlement Stipulation recognized that, subject to court approval, a non-opt out settlement class would be certified consisting of all holders of our common stock, except the defendants and their immediate families and their affiliates (the Class). The Settlement Stipulation acknowledged that updated disclosures were made with respect to the Public Exchange Offer and that the Public Exchange Offer expiration date was extended until March 11, 2011. The Settlement Stipulation also memorialized the parties' agreement that, following Court approval, MedQuist Holdings Inc. would conduct a short-form merger to acquire the remaining shares of our common stock at the same exchange ratio applicable under the Public Exchange Offer.
On April 19, 2011, the Court held a hearing to review the Settlement Stipulation and determine whether to preliminarily approve the settlement. On this same date, the Court entered a preliminary approval order (the Preliminary Approval Order) that, among other things, certified the Class for settlement purposes, set deadlines for providing notice of the settlement to Class members, and scheduled June 17, 2011 as the return date for a fairness hearing to determine final approval of the settlement. The Preliminary Approval Order also set May 27, 2011, as the deadline for the filing of a motion for final approval of the settlement, and June 3, 2011, as the deadline for any Class members to file objections to the settlement. The settlement will not become final until the Court determines, following a hearing, that the terms of the settlement are fair, reasonable and adequate, and in the best interests of the Settlement Class.
SEC Investigation of Former Officer
With respect to our historical billing practices, the SEC pursued civil litigation against our former chief financial officer, whose employment ended in July 2004. Pursuant to our bylaws, we had been providing indemnification for the legal fees for our former chief financial officer. In February 2011 we reached a settlement under which our former chief financial officer released us from our indemnification obligations to him upon his settlement of the litigation with the SEC and our payment to him of a negotiated amount. The former chief financial officer settled the SEC litigation and we made our settlement payment to him in May 2011. This settles the last remaining contingency related to our billing practices.
Item 1A. Risk Factors
There have been no material changes to the risk factors discussed in Part I, “Item 1A. Risk Factors,” in the 2010 Form 10-K. You should carefully consider the risks described in our 2010 Form 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2010 Form 10-K are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

18


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
 
Item 4. (Removed and Reserved)
Item 5. Other Information
None.
Item 6. Exhibits
(a) Exhibits
No.
 
Description
 
 
 
31.1
 
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
31.2
 
Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
 
 
 
32.1
 
Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
 
32.2
 
Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
 
 

19


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
MEDQUIST INC.
 
 
Date:
May 16, 2011
/s/ Peter Masanotti
 
 
 
Peter Masanotti 
 
 
 
President and Chief Executive Officer
(Principal Executive Officer) 
 
 
 
 
 
 
Date:
May 16, 2011
/s/ Anthony James
 
 
 
Anthony James
 
 
 
Chief Financial Officer
(Principal Financial Officer) 
 

20


Exhibit Index
No.
 
Description
31.1
 
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
31.2
 
Certification of Chief Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
 
 
32.1
 
Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
 
32.2
 
Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 

21
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki